title: BTI-322 for induction therapy after renal transplantation: a randomized study.
authors.affiliation: Department of Renal and Pancreatic Transplantation, Cliniques UCL Saint-Luc, Brussels, Belgium.
authors.forename: J P
authors.initials: JP
authors.lastname: Squifflet
authors.forename: T
authors.initials: T
authors.lastname: Besse
authors.forename: J
authors.initials: J
authors.lastname: Malaise
authors.forename: M
authors.initials: M
authors.lastname: Mourad
authors.forename: C
authors.initials: C
authors.lastname: Delcorde
authors.forename: J A
authors.initials: JA
authors.lastname: Hope
authors.forename: Y
authors.initials: Y
authors.lastname: Pirson
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D011239:Prednisolone / Q000627:therapeutic use; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; C105249:LO-CD2a; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine